These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28572020)

  • 1. Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's disease.
    Benge JF; Balsis S; Madeka T; Uhlman C; Lantrip C; Soileau MJ
    Parkinsonism Relat Disord; 2017 Aug; 41():104-108. PubMed ID: 28572020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the performance of the Montreal Cognitive Assessment in early stage Parkinson's disease.
    Kletzel SL; Hernandez JM; Miskiel EF; Mallinson T; Pape TL
    Parkinsonism Relat Disord; 2017 Apr; 37():58-64. PubMed ID: 28189463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease.
    Hendershott TR; Zhu D; Llanes S; Poston KL
    Parkinsonism Relat Disord; 2017 May; 38():31-34. PubMed ID: 28215728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.
    Zadikoff C; Fox SH; Tang-Wai DF; Thomsen T; de Bie RM; Wadia P; Miyasaki J; Duff-Canning S; Lang AE; Marras C
    Mov Disord; 2008 Jan; 23(2):297-9. PubMed ID: 18044697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease.
    Gill DJ; Freshman A; Blender JA; Ravina B
    Mov Disord; 2008 May; 23(7):1043-1046. PubMed ID: 18381646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes.
    Mills KA; Mari Z; Pontone GM; Pantelyat A; Zhang A; Yoritomo N; Powers E; Brandt J; Dawson TM; Rosenthal LS
    Parkinsonism Relat Disord; 2016 Dec; 33():107-114. PubMed ID: 27733275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease.
    Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of psychometric properties of the Beijing version of Montreal Cognitive Assessment in patients with idiopathic Parkinson's disease in China.
    Nie K; Zhang Y; Wang L; Zhao J; Huang Z; Gan R; Li S; Wang L
    J Clin Neurosci; 2012 Nov; 19(11):1497-500. PubMed ID: 22959678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.
    Brown DS; Bernstein IH; McClintock SM; Munro Cullum C; Dewey RB; Husain M; Lacritz LH
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):264-72. PubMed ID: 26177715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA.
    Hanna-Pladdy B; Enslein A; Fray M; Gajewski BJ; Pahwa R; Lyons KE
    Int J Neurosci; 2010 Aug; 120(8):538-43. PubMed ID: 20615057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study.
    Biundo R; Weis L; Bostantjopoulou S; Stefanova E; Falup-Pecurariu C; Kramberger MG; Geurtsen GJ; Antonini A; Weintraub D; Aarsland D
    J Neural Transm (Vienna); 2016 Apr; 123(4):431-8. PubMed ID: 26852137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construct Validity of the Montreal Cognitive Assessment (MoCA).
    Freitas S; Simões MR; Marôco J; Alves L; Santana I
    J Int Neuropsychol Soc; 2012 Mar; 18(2):242-50. PubMed ID: 22115097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Montreal Cognitive Assessment 5-minute protocol is a brief, valid, reliable, and feasible cognitive screen for telephone administration.
    Wong A; Nyenhuis D; Black SE; Law LS; Lo ES; Kwan PW; Au L; Chan AY; Wong LK; Nasreddine Z; Mok V
    Stroke; 2015 Apr; 46(4):1059-64. PubMed ID: 25700290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes on brief cognitive instruments over time in Parkinson's disease.
    Lessig S; Nie D; Xu R; Corey-Bloom J
    Mov Disord; 2012 Aug; 27(9):1125-8. PubMed ID: 22692724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computerized testing in Parkinson's disease: Performance deficits in relation to standard clinical measures.
    Flannery SL; Jowett T; Garvey A; Cutfield NJ; Machado L
    J Clin Exp Neuropsychol; 2018 Dec; 40(10):1062-1073. PubMed ID: 29978753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pill questionnaire in a nondemented Parkinson's disease population.
    Reginold W; Armstrong MJ; Duff-Canning S; Lang A; Tang-Wai D; Fox S; Rothberg B; Zadikoff C; Kennedy N; Gill D; Eslinger P; Mapstone M; Chou K; Persad C; Litvan I; Mast B; Marras C
    Mov Disord; 2012 Sep; 27(10):1308-11. PubMed ID: 22865587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease.
    Pagonabarraga J; Kulisevsky J; Llebaria G; García-Sánchez C; Pascual-Sedano B; Gironell A
    Mov Disord; 2008 May; 23(7):998-1005. PubMed ID: 18381647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive profile of Parkinson's disease patients: a comparative study between early-onset and late-onset Parkinson's disease.
    Tang H; Huang J; Nie K; Gan R; Wang L; Zhao J; Huang Z; Zhang Y; Wang L
    Int J Neurosci; 2016; 126(3):227-34. PubMed ID: 26001202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. French consensus procedure for assessing cognitive function in Parkinson's disease.
    Dujardin K; Auzou N; Lhommée E; Czernecki V; Dubois B; Fradet A; Maltete D; Meyer M; Pineau F; Schmitt E; Sellal F; Tison F; Vidal T; Azulay JP; Welter ML; Corvol JC; Durif F; Rascol O;
    Rev Neurol (Paris); 2016 Nov; 172(11):696-702. PubMed ID: 27318613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.